RU2757058C2 - Индуцируемые каспазы и способы использования - Google Patents

Индуцируемые каспазы и способы использования Download PDF

Info

Publication number
RU2757058C2
RU2757058C2 RU2019113152A RU2019113152A RU2757058C2 RU 2757058 C2 RU2757058 C2 RU 2757058C2 RU 2019113152 A RU2019113152 A RU 2019113152A RU 2019113152 A RU2019113152 A RU 2019113152A RU 2757058 C2 RU2757058 C2 RU 2757058C2
Authority
RU
Russia
Prior art keywords
cell
seq
leu
ser
lys
Prior art date
Application number
RU2019113152A
Other languages
English (en)
Russian (ru)
Other versions
RU2019113152A3 (https=
RU2019113152A (ru
Inventor
Эрик ОСТЕРТАГ
Девон ШЕДЛОК
Original Assignee
Посейда Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Посейда Терапьютикс, Инк. filed Critical Посейда Терапьютикс, Инк.
Publication of RU2019113152A publication Critical patent/RU2019113152A/ru
Publication of RU2019113152A3 publication Critical patent/RU2019113152A3/ru
Application granted granted Critical
Publication of RU2757058C2 publication Critical patent/RU2757058C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22062—Caspase-9 (3.4.22.62)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22036—Caspase-1 (3.4.22.36), i.e. interleukin-1-beta-convertase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
RU2019113152A 2016-10-06 2017-10-06 Индуцируемые каспазы и способы использования RU2757058C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662405184P 2016-10-06 2016-10-06
US62/405,184 2016-10-06
PCT/US2017/055661 WO2018068022A1 (en) 2016-10-06 2017-10-06 Inducible caspases and methods for use

Publications (3)

Publication Number Publication Date
RU2019113152A RU2019113152A (ru) 2020-11-06
RU2019113152A3 RU2019113152A3 (https=) 2021-03-12
RU2757058C2 true RU2757058C2 (ru) 2021-10-11

Family

ID=60190939

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019113152A RU2757058C2 (ru) 2016-10-06 2017-10-06 Индуцируемые каспазы и способы использования

Country Status (20)

Country Link
US (4) US11377480B2 (https=)
EP (2) EP4640273A3 (https=)
JP (1) JP7054694B2 (https=)
KR (1) KR102447083B1 (https=)
CN (1) CN110267980A (https=)
AU (1) AU2017339511B2 (https=)
BR (1) BR112019006865A2 (https=)
DK (1) DK3523325T3 (https=)
ES (1) ES3051391T3 (https=)
FI (1) FI3523325T3 (https=)
HR (1) HRP20251387T1 (https=)
IL (1) IL265664B2 (https=)
LT (1) LT3523325T (https=)
MX (1) MX2019003983A (https=)
PL (1) PL3523325T3 (https=)
PT (1) PT3523325T (https=)
RS (1) RS67390B1 (https=)
RU (1) RU2757058C2 (https=)
SI (1) SI3523325T1 (https=)
WO (1) WO2018068022A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2792795C1 (ru) * 2022-05-12 2023-03-24 Федеральное государственное бюджетное учреждение науки "Федеральный исследовательский центр "Пущинский научный центр биологических исследований Российской академии наук" (ФИЦ ПНЦБИ РАН) Способ получения каспазы-3
WO2025029171A1 (ru) * 2023-07-29 2025-02-06 Общество с ограниченной ответственностью "Генетические технологии" (ООО "Генетические технологии") Векторы экспрессии на основе аденоассоциированного вируса

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3523325T (pt) 2016-10-06 2025-11-12 Poseida Therapeutics Inc Caspases induzíveis e métodos de utilização
WO2020037142A1 (en) 2018-08-17 2020-02-20 Yale University Compositions and methods for high-throughput activation screening to boost t cell effector function
US20220042038A1 (en) 2018-12-20 2022-02-10 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
CN114761424B (zh) 2019-09-05 2025-09-19 波赛达治疗公司 同种异体细胞组合物和使用方法
CA3162246A1 (en) 2019-12-20 2021-06-24 Poseida Therapeutics, Inc. Anti-muc1 compositions and methods of use
WO2021183795A1 (en) 2020-03-11 2021-09-16 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
EP4298205A1 (en) 2021-02-23 2024-01-03 Poseida Therapeutics, Inc. Genetically modified induced pluripotent stem cells and methods of use thereof
EP4413141A1 (en) 2021-10-04 2024-08-14 Poseida Therapeutics, Inc. Transposon compositions and methods of use thereof
CN113999873B (zh) * 2021-12-31 2022-05-20 北京市疾病预防控制中心 一种基因修饰的非人动物的构建方法及其应用
CN114736306B (zh) * 2022-03-01 2024-04-19 中国科学院深圳先进技术研究院 一种受化学调控的蛋白酶工具及其配套底物
WO2023173137A1 (en) * 2022-03-11 2023-09-14 Yale University Compositions and methods for efficient and stable genetic modification of eukaryotic cells
CN118185901B (zh) * 2022-12-12 2025-03-21 北京精缮生物科技有限责任公司 一种PBase蛋白、融合蛋白、核酸和基因整合系统及应用
EP4669745A1 (en) 2023-02-21 2025-12-31 Poseida Therapeutics, Inc. COMPOSITIONS AND GENOMIC EDITING PROCESSES
JP2026507648A (ja) 2023-02-21 2026-03-04 ポセイダ セラピューティクス，インコーポレイティド ゲノム編集のための組成物及び方法
KR20250173518A (ko) 2023-04-05 2025-12-10 포세이다 테라퓨틱스, 인크. 트랜스포사제 폴리뉴클레오티드 및 그의 용도
WO2025038655A1 (en) 2023-08-14 2025-02-20 Ponce Therapeutics, Inc. Multimerizer pharmaceutical compositions of rimiducid
WO2026080393A1 (en) 2024-10-07 2026-04-16 Poseida Therapeutics, Inc. Compositions and methods for use in car cell therapies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200400392A1 (ru) * 2001-09-04 2004-10-28 Йеда Рисерч Энд Дивелопмент Ко.Лтд. Связывающий каспазу-8 белок, его получение и применение
WO2015134877A1 (en) * 2014-03-07 2015-09-11 Bellicum Pharmaceuticals, Inc. Caspase polypeptides having modified activity and uses thereof
WO2016135470A1 (en) * 2015-02-24 2016-09-01 Ucl Business Plc Chimeric protein

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4766067A (en) 1985-05-31 1988-08-23 President And Fellows Of Harvard College Gene amplification
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US4795699A (en) 1987-01-14 1989-01-03 President And Fellows Of Harvard College T7 DNA polymerase
US4921794A (en) 1987-01-14 1990-05-01 President And Fellows Of Harvard College T7 DNA polymerase
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5142033A (en) 1988-09-23 1992-08-25 Hoffmann-La Roche Inc. Structure-independent DNA amplification by the polymerase chain reaction
US5091310A (en) 1988-09-23 1992-02-25 Cetus Corporation Structure-independent dna amplification by the polymerase chain reaction
US5066584A (en) 1988-09-23 1991-11-19 Cetus Corporation Methods for generating single stranded dna by the polymerase chain reaction
US4994370A (en) 1989-01-03 1991-02-19 The United States Of America As Represented By The Department Of Health And Human Services DNA amplification technique
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6835394B1 (en) 1999-12-14 2004-12-28 The Trustees Of The University Of Pennsylvania Polymersomes and related encapsulating membranes
WO2006133398A2 (en) 2005-06-08 2006-12-14 Invitrogen Corporation In vitro activated donor t-cells to promote transplant engraftment
JP4563491B1 (ja) 2009-07-07 2010-10-13 株式会社片岡製作所 レーザ加工機
US8808748B2 (en) 2010-04-20 2014-08-19 Vindico NanoBio Technology Inc. Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
DK2661275T3 (en) 2011-01-07 2019-04-15 Poseida Therapeutics Inc COMPOSITIONS AND METHODS FOR ADMINISTRATING THE HIGH OXYGEN EFFICIENCY TO TUMORS FOR THE ADMINISTRATION
CA2912172A1 (en) 2013-06-05 2014-12-11 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
CA2957552C (en) 2014-08-08 2024-01-16 Vindico Nanobiotechnology, Llc Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors
WO2016090111A1 (en) 2014-12-05 2016-06-09 Vindico NanoBio Technology Inc. Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors
US10456452B2 (en) 2015-07-02 2019-10-29 Poseida Therapeutics, Inc. Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
US20170000743A1 (en) 2015-07-02 2017-01-05 Vindico NanoBio Technology Inc. Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles
US9834743B2 (en) 2016-04-23 2017-12-05 Seid Mehdi Naeini Removing pets urin, odor and mildew out of hand made rugs
ES2865481T3 (es) 2016-04-29 2021-10-15 Poseida Therapeutics Inc Micelas basadas en poli(histidina) para la complejación y el aporte de proteínas y ácidos nucleicos
PT3523325T (pt) 2016-10-06 2025-11-12 Poseida Therapeutics Inc Caspases induzíveis e métodos de utilização

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200400392A1 (ru) * 2001-09-04 2004-10-28 Йеда Рисерч Энд Дивелопмент Ко.Лтд. Связывающий каспазу-8 белок, его получение и применение
WO2015134877A1 (en) * 2014-03-07 2015-09-11 Bellicum Pharmaceuticals, Inc. Caspase polypeptides having modified activity and uses thereof
WO2016135470A1 (en) * 2015-02-24 2016-09-01 Ucl Business Plc Chimeric protein

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KARIN C STRAATHOF ET AL, A inducible caspase 9 safety switch for T-cell therapy, BLOOD, 2005, vol. 105, no. 11, pp. 4247 - 4254. *
KARIN C STRAATHOF ET AL, A inducible caspase 9 safety switch for T-cell therapy, BLOOD, 2005, vol. 105, no. 11, pp. 4247 - 4254. TEY ET AL, Inducible Caspase 9 Suicide Gene to Improve the Safety of Allodepleted T Cells after Haploidentical Stem Cell Transplantation, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, vol. 13, no. 8, pp. 913 - 924. *
TEY ET AL, Inducible Caspase 9 Suicide Gene to Improve the Safety of Allodepleted T Cells after Haploidentical Stem Cell Transplantation, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, vol. 13, no. 8, pp. 913 - 924. *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2792795C1 (ru) * 2022-05-12 2023-03-24 Федеральное государственное бюджетное учреждение науки "Федеральный исследовательский центр "Пущинский научный центр биологических исследований Российской академии наук" (ФИЦ ПНЦБИ РАН) Способ получения каспазы-3
RU2812469C1 (ru) * 2023-07-29 2024-01-30 Общество с ограниченной ответственностью "Генетические технологии" (ООО "Генетические технологии") Комбинация векторов для терапии врожденной дисфункции коры надпочечников
RU2812471C1 (ru) * 2023-07-29 2024-01-30 Общество с ограниченной ответственностью "Генетические технологии" (ООО "Генетические технологии") Набор векторов экспрессии на основе аденоассоциированного вируса
RU2812468C1 (ru) * 2023-07-29 2024-01-30 Общество с ограниченной ответственностью "Генетические технологии" (ООО "Генетические технологии") Векторы экспрессии на основе аденоассоциированного вируса
WO2025029171A1 (ru) * 2023-07-29 2025-02-06 Общество с ограниченной ответственностью "Генетические технологии" (ООО "Генетические технологии") Векторы экспрессии на основе аденоассоциированного вируса

Also Published As

Publication number Publication date
EP3523325A1 (en) 2019-08-14
RU2019113152A3 (https=) 2021-03-12
EP3523325B1 (en) 2025-08-06
PL3523325T3 (pl) 2026-02-23
EP4640273A3 (en) 2026-01-21
CA3038708A1 (en) 2018-04-12
KR20190066616A (ko) 2019-06-13
WO2018068022A1 (en) 2018-04-12
US20260001929A1 (en) 2026-01-01
RS67390B1 (sr) 2025-11-28
EP4640273A2 (en) 2025-10-29
PT3523325T (pt) 2025-11-12
HRP20251387T1 (hr) 2025-12-19
KR102447083B1 (ko) 2022-09-26
JP7054694B2 (ja) 2022-04-14
US20230348553A1 (en) 2023-11-02
US12358966B2 (en) 2025-07-15
SI3523325T1 (sl) 2026-01-30
IL265664A (en) 2019-05-30
LT3523325T (lt) 2025-11-25
US11377480B2 (en) 2022-07-05
DK3523325T3 (da) 2025-11-10
MX2019003983A (es) 2019-06-10
JP2019528774A (ja) 2019-10-17
US20230002469A1 (en) 2023-01-05
AU2017339511A1 (en) 2019-04-18
IL265664B1 (en) 2023-10-01
FI3523325T3 (fi) 2025-11-14
US11718656B2 (en) 2023-08-08
IL265664B2 (en) 2024-02-01
US20190225667A1 (en) 2019-07-25
CN110267980A (zh) 2019-09-20
BR112019006865A2 (pt) 2019-06-25
RU2019113152A (ru) 2020-11-06
AU2017339511B2 (en) 2021-12-02
ES3051391T3 (en) 2025-12-29

Similar Documents

Publication Publication Date Title
RU2757058C2 (ru) Индуцируемые каспазы и способы использования
KR102949204B1 (ko) 알부민 좌위로부터 트랜스진을 발현하기 위한 조성물 및 방법
JP2025028917A (ja) 核酸構築物及び使用方法
JP2021502058A (ja) Ｒｎａを編集するための組成物および方法
KR20220155981A (ko) 미성숙 종결 코돈-매개 장애를 치료하기 위한 방법 및 조성물
CN113227385A (zh) 核酸分子及其用于非病毒基因疗法的用途
KR20240133774A (ko) 압타머-매개된 조정된 선택적 스플라이싱에 의한 유전자 발현 제어
CN113710693B (zh) Dna结合结构域反式激活因子及其用途
JP2022514465A (ja) 第ｉｘ因子を発現するレンチウイルスベクターの使用
US20250000975A1 (en) Preparation for chimeric antigen receptor immune cell constructed on basis of gas6 and use of chimeric antigen receptor immune cell
CN116685329B (zh) 核酸构建体及其用于治疗脊髓性肌肉萎缩症的用途
KR20240025507A (ko) 미성숙 종결 코돈-매개 장애를 치료하기 위한 방법 및 조성물
CN107207603A (zh) 趋化因子‑免疫球蛋白融合多肽，其组合物、制备方法以及用途
US20240207448A1 (en) Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp)
CA3038708C (en) Inducible caspases and methods for use
WO2009071679A1 (en) Novel aav vector and uses thereof
CN116917471A (zh) 溶酶体酸性脂肪酶变体及其用途
HK40011626B (en) Inducible caspases and methods for use
HK40011626A (en) Inducible caspases and methods for use
KR102957630B1 (ko) 핵산 구조체 및 사용 방법
WO1999003999A1 (en) Methods and compositions for inhibiting the proinflammatory response
CA2261183A1 (en) Adenoviral transfer vector for the gene transport of a dna sequence
RU2819144C2 (ru) Молекулы нуклеиновой кислоты и пути их применения
CN115803438A (zh) 用于cd3+细胞体外和体内表达基因治疗产物的启动子序列
Spielmann et al. GROWTH FACTOR GENE THERAPY IN DIABETIC PIGS: TRANSGENIC KERATINOCYTE TRANSPLANTATION TO FULL-THICKNESS WOUNDS